9VC logo

Atai Life Sciences DB:9VC Stock Report

Last Price

€1.59

Market Cap

€264.0m

7D

26.3%

1Y

-12.8%

Updated

09 Jan, 2025

Data

Company Financials +

Atai Life Sciences N.V.

DB:9VC Stock Report

Market Cap: €264.0m

9VC Stock Overview

A clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. More details

9VC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Revenue is forecast to grow 65.72% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Makes less than USD$1m in revenue ($331K)

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years


My Notes

Capture your thoughts, links and company narrative

Atai Life Sciences N.V. Competitors

PharmaSGP Holding

XTRA:PSG

€318.9m

Apontis Pharma

XTRA:APPH

€84.1m

Pierrel

DB:2FJ0

€92.8m

Cantourage Group

XTRA:HIGH

€60.1m

Price History & Performance

Summary of share price highs, lows and changes for Atai Life Sciences
Historical stock prices
Current Share PriceUS$1.59
52 Week HighUS$2.48
52 Week LowUS$0.95
Beta1.19
1 Month Change7.72%
3 Month Change64.26%
1 Year Change-12.76%
3 Year Change-71.09%
5 Year Changen/a
Change since IPO-89.84%

Recent News & Updates

Recent updates

Shareholder Returns

9VCDE PharmaceuticalsDE Market
7D26.3%1.2%1.2%
1Y-12.8%-14.1%10.1%

Return vs Industry: 9VC exceeded the German Pharmaceuticals industry which returned -15% over the past year.

Return vs Market: 9VC underperformed the German Market which returned 9.4% over the past year.

Price Volatility

Is 9VC's price volatile compared to industry and market?
9VC volatility
9VC Average Weekly Movement17.6%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 9VC's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 9VC's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
201883Srini Raowww.atai.life

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology.

Atai Life Sciences N.V. Fundamentals Summary

How do Atai Life Sciences's earnings and revenue compare to its market cap?
9VC fundamental statistics
Market cap€263.98m
Earnings (TTM)-€124.89m
Revenue (TTM)€321.43k

821.3x

P/S Ratio

-2.1x

P/E Ratio

Is 9VC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9VC income statement (TTM)
RevenueUS$331.00k
Cost of RevenueUS$0
Gross ProfitUS$331.00k
Other ExpensesUS$128.93m
Earnings-US$128.60m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.77
Gross Margin100.00%
Net Profit Margin-38,852.87%
Debt/Equity Ratio17.2%

How did 9VC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 19:32
End of Day Share Price 2025/01/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Atai Life Sciences N.V. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Sumant Satchidanand KulkarniCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.